LISATA THERAPEUTICS INC (LSTA) Stock Price, Forecast & Analysis
USA - NASDAQ:LSTA - US1280583022 - Common Stock
LSTA Key Statistics, Chart & Performance
The current stock price of LSTA is 2.06 USD. In the past month the price decreased by -13.08%. In the past year, price decreased by -29.21%.
LSTA Latest News, Press Relases and Analysis
LSTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About LSTA
Company Profile
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Company Info
LISATA THERAPEUTICS INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY US
Employees: 26
Phone: 19082292590
LISATA THERAPEUTICS INC / LSTA FAQ
What does LISATA THERAPEUTICS INC do?
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Can you provide the latest stock price for LISATA THERAPEUTICS INC?
The current stock price of LSTA is 2.06 USD. The price decreased by -12.34% in the last trading session.
What is the dividend status of LISATA THERAPEUTICS INC?
LSTA does not pay a dividend.
What is the ChartMill rating of LISATA THERAPEUTICS INC stock?
LSTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does LISATA THERAPEUTICS INC have?
LISATA THERAPEUTICS INC (LSTA) currently has 26 employees.
What is LISATA THERAPEUTICS INC worth?
LISATA THERAPEUTICS INC (LSTA) has a market capitalization of 18.05M USD. This makes LSTA a Nano Cap stock.
LSTA Technical Analysis
LSTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LSTA. LSTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LSTA Financial Highlights
Over the last trailing twelve months LSTA reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 15.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.21% | ||
| ROE | -89.99% | ||
| Debt/Equity | 0 |
LSTA Forecast & Estimates
9 analysts have analysed LSTA and the average price target is 21.08 USD. This implies a price increase of 923.3% is expected in the next year compared to the current price of 2.06.